Hilzinger Buys Outlook Stock
Outlook Therapeutics director Kurt J. Hilzinger purchases company stock, showing insider confidence. The buy totals $176,520.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.